Innovation

Pugatch Consilium releases new report on National Biotechnology Innovation strategies

Posted by:

Today Pugatch Consilium releases a new report on the development of national innovation strategies in the biotech sector commissioned by the Biotechnology Industry Organization (BIO).

The report, Building the Bioeconomy Examining National Biotechnology Industry Development Strategies, provides an overview of national innovation strategies, policies and best practices that relate to the building of a world-class biotechnology sector. It identifies key enabling policy input factors ranging from human capital, protection of intellectual property to infrastructure for research and development.

Through case ...

Continue Reading →
0

New Report on the Value of Cross-Border Data

Posted by:

Pugatch Consilium has launched a new report, At the Cutting Edge, on the benefits of cross-border data to consumers, companies and governments. The report considers the value and applications of cross-border data in different countries around the world today. It analyzes a wide range of personal, social and economic benefits using case studies and anecdotes as well as statistical analysis. The report also presents a set of enabling and deterrent factors of these flows. Download a copy from the Continue Reading →

0

The US Chamber of Commerce and Pugatch Consilium’s Dr David Torstensson launch 2nd edition of the GIPC IP Index

Posted by:

Dr David Torstensson, Partner with Pugatch Consilium, is speaking at the international launch of the 2013 GIPC IP Index at the US Chamber of Commerce in Washington DC, USA. Pugatch Consilium has developed the GIPC IP Index in partnership with the US Chamber of Commerce’s Global Intellectual Property Center. The Index is a one-of-a-kind instrument that benchmarks and measures the national IP environment in 25 countries.

The launch of the 2013 Index will take place on January 29 2014 starting at ...

Continue Reading →
0

When National Champions Fall

Posted by:

The case of Teva requires us to revise our thinking about national champions and national interests;
Prof. Meir Perez Pugatch addresses the current situation with Teva pharmaceuticals – the biggest generics company in the world – in Israel and how it has been impacted by the patent expiration of Copaxon. Full article at Pharmaphorum Media

Continue Reading →
0

Thoughts from ISPOR 2013

Posted by:

Earlier this month, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its 16th Annual European Congress, in Dublin. ISPOR is a non-profit organization founded in 1995 for educational and scientific purposes. The cylinder-shaped Convention Centre building overlooking the River Liffey served as the venue for an impressive event which featured over 1800 presentations and was visited by circa 3800 people from a variety of professional fields including health technology developers and assessors, regulators, health economists, healthcare policymakers, academia, ...

Continue Reading →
0

Stop all the clocks – a WH Auden approach to EU policymaking?

Posted by:

As the knowledge economy becomes a more fundamental part of the global economy, so grows the interest in, and proliferation of, policies devoted to strengthening innovation and the knowledge base. But it is not always an easy or straightforward process for policymakers’ knowledge to keep pace with the speed of innovation in ‘real world’ business models, methods and practices.

This week, our Founder and MD, Professor Meir Pugatch, wearing his ‘other hat’ as a visiting Professor at Maastricht University, took a ...

Continue Reading →
0

When is an incremental innovation not an incremental innovation?

Posted by:

The UK government recently announced that it would be offering all toddlers the flu vaccine as a nasal spray rather than as the traditional injection. All children aged two will be offered vaccination against flu, with the UK becoming the first country to offer the vaccine to healthy children free of charge. The new immunisation programme aims to give annual protection to 650,000 two-year-olds using a nasal spray called Fluenz.

As a mother, I was delighted to hear this news. As ...

Continue Reading →
0
Page 5 of 11 «...34567...»